Ind Swift

Chandigarh, India Founded: 1995 • Age: 31 yrs Listed
API CDMO also having capabilities to manufacture HPAPIs and intermediates
Request Access
Report Incorrect Data
Page last updated

About Ind Swift

Ind Swift is a publicly listed company based in Chandigarh (India) founded in 1995. API CDMO also having capabilities to manufacture HPAPIs and intermediates. The company has 1,250 employees. Its chief executive, as recorded, is Gopal Munjal. Its Indian entity Ind Swift Laboratories Limited reported revenue of ₹688 Cr. Ind Swift offers products and services including APIs, Formulations, CRAMS, and Research Services. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

Ind-Swift Laboratories Ltd. was established in 1995 in Chandigarh, India, focusing on API manufacturing and CRAMS in the pharmaceutical sector. Operations span six manufacturing sites across India and an independent RD center, enabling API development, finished dosage forms, and non-infringing processes. Services include custom synthesis, preclinical supply, process RD, contract manufacturing of HPAPIs, and analytical plus regulatory support. Facilities are approved by FDA, EDQM, TGA, PMDA, KFDA, and other agencies.

  • Headquarters Chandigarh, India
  • Employees 1,250
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website indswiftlabs.com
  • Social LinkedIn X Facebook Instagram
  • Legal Name Ind-Swift Laboratories Ltd.
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹3,102 Cr

    INDSWFTLAB · NSE

  • Share Price
    ₹348.20

    -2.40% today

  • Revenue
    ₹641 Cr

    FY 2025-26 · +14.2% YoY

  • EBITDA
    ₹34.09 Cr

    Margin 5.3%

  • Net Profit
    ₹49.48 Cr

    FY 2025-26 · +2695.5% YoY

  • P/E (TTM)
    32.6x

    P/B 2.0x

  • ROE
    3.7%

    ROCE 4.4%

  • Debt / Equity
    0.01

    Interest cover 26.9x

  • Employee Count
    1,250

Products & Services of Ind Swift

Ind Swift offers a comprehensive portfolio of products and services, including APIs, Formulations, CRAMS, and Research Services.

APIs
Pharmaceutical Ingredients

Manufactures high-quality active ingredients for global pharmaceutical use.

Formulations
Drug Production

Develops and supplies finished pharmaceutical formulations.

CRAMS
Contract Services

Provides contract research and manufacturing for drug development.

Research Services
R&D Support

Offers process optimization and new product development services.

Board of directors of Ind Swift Laboratories Limited (Ind Swift)

Ind Swift Laboratories Limited is the primary company behind Ind Swift. The board of Ind Swift Laboratories Limited currently have 8 directors; the longest-serving is Himanshu Jain, appointed in 1995. 26 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Himanshu Jain
DIN 00014533
Whole-time director04 Jan 199531 yrs 10 moInd Swift Laboratories Limited
Navrattan Munjal
DIN 00015096
Managing Director04 Jan 199531 yrs 10 moInd Swift Laboratories Limited
Rishav Mehta
DIN 03028663
Whole-time director23 Mar 201016 yrs 7 moInd Swift Laboratories Limited
Neerja Chathley
DIN 08448077
Director10 May 20197 yrs 5 moInd Swift Laboratories Limited
Sahil Munjal
DIN 00015407
Whole-time director13 Feb 20206 yrs 8 moInd Swift Laboratories Limited
Rajinder Kumar Gupta
DIN 09212540
Director23 Jun 20215 yrs 4 moInd Swift Laboratories Limited
Subodh Gupta
DIN 01393423
Director05 Jul 20251 yr 4 moInd Swift Laboratories Limited
Prabhat Khurana
DIN 03289193
Director05 Jul 20251 yr 4 moInd Swift Laboratories Limited

People of Ind Swift

8 people are tracked at Ind Swift (8 in leadership); the tracked headcount is 1,250.

NameRoleGroup
Gopal Munjal
CEO & MDLeadership
Nav Rattan Munjal
Vice Chairman & Managing DirectorLeadership
Anil R Agrawal
Chief Operating OfficerLeadership
Vikas Narendra
President, U.S OperationsLeadership
Sahil Munjal
President, OperationsLeadership
Himanshu Jain
Joint Managing DirectorLeadership
Sunil Deshmukh
CEOLeadership
Dr Ashok Prasad
Senior Vice President & Head : R&d + CramsLeadership
Premium access

Complete people profiles for Ind Swift

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Ind Swift

Ind Swift is a publicly listed company on the NSE with ticker symbol INDSWFTLAB in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date03 Jun 2000
  • Listed onBSE: 532305
  • Listed entityInd-Swift Laboratories Ltd.
  • Exchange sectorHealth technology
  • ISININE915B01019
  • Share price₹369.70 (+2.31% on the day) · 2026-10-14
  • Market capitalisation₹3,149 Cr
  • Price to earnings55.2
  • EPS (diluted, trailing year)₹6.69
  • Volume (last session)354,401

Financials of Ind Swift

Exchange-reported figures of Ind Swift Laboratories Limited, the listed company behind Ind Swift (NSE: INDSWFTLAB).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹641 Cr
+14.2% YoY
EBITDA
₹34.09 Cr
+275.8% YoY
Profit After Tax
₹49.48 Cr
+2695.5% YoY
Net Worth
₹1,384 Cr
+16.6% YoY
Total Assets
₹1,422 Cr
+16.1% YoY
Total Debt
₹17.91 Cr
-4.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6415621,2811,2071,039891780
Revenue growth+14.2%-56.2%+6.1%+16.2%+16.5%+14.3%-
EBITDA34.09(19.39)254203196183144
EBITDA margin+5.3%-3.5%+19.9%+16.8%+18.8%+20.5%+18.5%
Profit before tax49.0525858286.5212.5318.01(19.77)
Net profit49.481.7714061.511.30(3.15)(21.26)
Net profit margin+7.7%+0.3%+11.0%+5.1%+0.1%-0.4%-2.7%
EPS (₹)4.8436.4471.247.96(0.36)(0.53)(3.54)
Balance sheet
Total assets1,4221,2259491,5621,5711,6251,687
Net worth1,3841,187931682601604641
Total debt17.9118.7816.638629531,0051,031
Cash & bank43042543218.2021.4811.6010.58
Net working capital713612445902846750680
Cash flow
Cash from operations(68.17)(28.69)(163)195150135125
Cash from investing(68.90)(113)(104)(13.37)4.77(10.17)(9.10)
Cash from financing14272.42699(186)(141)(124)(133)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue240191170151159153138129
Revenue growth (YoY)+51.6%+25.4%+22.8%+17.1%+1226.4%+360.5%--
Other income7.607.652.2227.5811.8614.5822016.64
EBITDA44.8833.1915.42(1.68)7.473.60(9.19)(7.37)
EBITDA margin+18.7%+17.3%+9.1%-1.1%+4.7%+2.4%-6.6%-5.7%
Depreciation7.777.588.128.846.986.687.445.81
Interest1.330.71(2.43)0.672.011.15(26.76)10.03
Profit before tax43.3832.5511.9516.3910.3410.35230(6.57)
Tax9.237.99(3.15)6.872.301.718.19(1.08)
Net profit34.1524.5615.109.528.048.64222(5.49)
EPS (₹)3.922.841.761.130.961.1730.08(0.82)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6365501,6731,152988857752
Revenue growth+15.7%-67.1%+45.2%+16.6%+15.4%+13.9%-
EBITDA35.23(12.94)299195192180142
EBITDA margin+5.5%-2.4%+17.9%+17.0%+19.4%+21.1%+18.9%
Profit before tax50.2226459479.198.0016.12(19.57)
Net profit50.708.0514655.86(2.57)(4.40)(20.87)
Net profit margin+8.0%+1.5%+8.7%+4.9%-0.3%-0.5%-2.8%
EPS (₹)4.9737.2579.777.10(0.95)(0.74)(3.48)
Balance sheet
Total assets1,4081,2121,0281,5471,5941,6511,691
Net worth1,3711,178812675633639645
Total debt17.9115.332008549449961,031
Cash & bank4154104889.969.389.958.84
Net working capital617545472833789700675
Cash flow
Cash from operations(40.19)(45.30)(166)183136135123
Cash from investing(100)(110)(27.71)(13.69)2.76(10.17)(10.15)
Cash from financing14577.44658(168)(140)(124)(133)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue235186173153156148150122
Revenue growth (YoY)+50.2%+25.7%+15.5%+26.0%+5672.3%+385.9%--
Other income7.607.632.2123.8911.8614.5821616.63
Total expenses193153158150148145158123
EBITDA41.7533.0915.153.238.183.07(8.69)(1.66)
EBITDA margin+17.8%+17.8%+8.8%+2.1%+5.2%+2.1%-5.8%-1.4%
Depreciation7.777.588.088.846.986.687.445.81
Interest1.330.71(2.44)0.672.011.15(26.76)10.03
Profit before tax40.2532.4311.7217.6111.059.82226(0.87)
Tax9.217.98(3.22)6.872.301.718.050.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 06 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue240191170151159153138129
Revenue growth (YoY)+51.6%+25.4%+22.8%+17.1%+1226.4%+360.5%--
Other income7.607.652.2227.5811.8614.5822016.64
EBITDA44.8833.1915.42(1.68)7.473.60(9.19)(7.37)
EBITDA margin+18.7%+17.3%+9.1%-1.1%+4.7%+2.4%-6.6%-5.7%
Depreciation7.777.588.128.846.986.687.445.81
Interest1.330.71(2.43)0.672.011.15(26.76)10.03
Profit before tax43.3832.5511.9516.3910.3410.35230(6.57)
Tax9.237.99(3.15)6.872.301.718.19(1.08)
Net profit34.1524.5615.109.528.048.64222(5.49)
EPS (₹)3.922.841.761.130.961.1730.08(0.82)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6415621,2811,2071,039891780
Revenue growth+14.2%-56.2%+6.1%+16.2%+16.5%+14.3%-
Other income46.9730543233.5043.5022.7033.40
Total expenses6075811,0271,005843709635
Employee cost0.00118153136127107103
EBITDA34.09(19.39)254203196183144
EBITDA margin+5.3%-3.5%+19.9%+16.8%+18.8%+20.5%+18.5%
Depreciation30.6124.4853.3057.3613187.2990.06
Interest1.402.9251.1092.1795.55100107
Profit before tax49.0525858286.5212.5318.01(19.77)
Tax7.737.2716038.6914.6821.161.42
Net profit49.481.7714061.511.30(3.15)(21.26)
Net profit margin+7.7%+0.3%+11.0%+5.1%+0.1%-0.4%-2.7%
EPS (₹)4.8436.4471.247.96(0.36)(0.53)(3.54)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital86.8482.9459.0959.8159.8159.8159.81
Reserves & surplus1,2971,030872622541544581
Shareholders' funds (net worth)1,3841,187931682601604641
Minority interest(0.06)(0.03)(0.02)0.00(0.11)(0.09)0.00
Secured loans9.314.698.17796906972973
Unsecured loans8.6014.098.4665.7746.9933.1057.97
Total debt17.9118.7816.638629531,0051,031
Total liabilities1,4221,2259491,5621,5711,6251,687
Assets
Gross block70065511.021,3341,3221,3171,357
Net block3042737.66587630753843
Capital work in progress12.410.000.007.7110.3118.8411.45
Investments24821311130.3429.0635.5317.45
Inventories14811410.46439428376343
Sundry debtors199165169505455432396
Cash & bank balances43042543218.2021.4811.6010.58
Loans & advances18912249.62202171125113
Total current assets9658266611,1651,075944863
Total current liabilities252214216262230194183
Net working capital713612445902846750680
Total assets1,4221,2259491,5621,5711,6251,687
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash42549418.2021.4811.6010.5829.97
Net cash from operating activities(68.17)(28.69)(163)195150135125
Net cash from investing activities(68.90)(113)(104)(13.37)4.77(10.17)(9.10)
Net cash from financing activities14272.42699(186)(141)(124)(133)
Net change in cash4.74(68.82)431(4.41)14.171.03(17.12)
Closing cash43042543218.2021.4811.6010.58
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.2%-56.2%+6.1%+16.2%+16.5%+14.3%-
EBITDA growth+275.8%-107.6%+25.5%+3.5%+7.0%+26.6%-
PBT growth-80.3%-55.7%+572.4%+590.5%-30.4%+9998.0%-
Net income growth+2695.5%-98.7%+128.4%+4631.5%+141.3%+85.2%-
Revenue CAGR (3Y)-18.7%-17.9%+12.9%+15.7%+11.1%+5.2%+2.9%
EBITDA CAGR (3Y)-43.9%-+11.6%+12.0%+15.8%+11.4%+13.0%
Profitability & leverage
Net income margin+6.6%+43.6%+32.9%+4.0%-0.2%-0.4%-2.7%
Return on capital employed+4.4%+3.1%+20.7%+14.8%0.0%0.0%0.0%
Return on net worth+3.7%+1.8%+19.3%+13.2%0.0%0.0%0.0%
Debt / equity0.010.020.612.012.462.522.85
Long-term debt / equity0.010.010.531.772.172.202.43
Interest cover26.92-9.3225.4363.48147.96104.91197.88
Efficiency & per share
Fixed asset turnover0.961.722.201.060.930.800.68
Inventory turnover4.959.215.702.782.582.482.36
Debtors turnover3.583.443.802.512.342.152.09
EPS (₹)4.9736.4471.247.96(0.36)(0.53)(3.54)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)159.28159.86157.6483.3667.6365.6769.49
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue235186173153156148150122
Revenue growth (YoY)+50.2%+25.7%+15.5%+26.0%+5672.3%+385.9%--
Other income7.607.632.2123.8911.8614.5821616.63
Total expenses193153158150148145158123
EBITDA41.7533.0915.153.238.183.07(8.69)(1.66)
EBITDA margin+17.8%+17.8%+8.8%+2.1%+5.2%+2.1%-5.8%-1.4%
Depreciation7.777.588.088.846.986.687.445.81
Interest1.330.71(2.44)0.672.011.15(26.76)10.03
Profit before tax40.2532.4311.7217.6111.059.82226(0.87)
Tax9.217.98(3.22)6.872.301.718.050.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6365501,6731,152988857752
Revenue growth+15.7%-67.1%+45.2%+16.6%+15.4%+13.9%-
Other income46.9630447933.2842.5023.1336.02
Total expenses6015631,374957796676610
Employee cost0.00115233133125104100
EBITDA35.23(12.94)299195192180142
EBITDA margin+5.5%-2.4%+17.9%+17.0%+19.4%+21.1%+18.9%
Depreciation30.5724.4880.4157.3613187.2990.06
Interest1.402.9210492.1795.55100107
Profit before tax50.2226459479.198.0016.12(19.57)
Tax7.668.0557.7636.7213.7020.521.23
Net profit50.708.0514655.86(2.57)(4.40)(20.87)
Net profit margin+8.0%+1.5%+8.7%+4.9%-0.3%-0.5%-2.8%
EPS (₹)4.9737.2579.777.10(0.95)(0.74)(3.48)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital86.8482.9481.4159.8159.8159.8159.81
Reserves & surplus1,2841,021731616573579585
Shareholders' funds (net worth)1,3711,178812675633639645
Secured loans9.314.694.87839929964973
Unsecured loans8.6010.6419514.3414.8832.9457.97
Total debt17.9115.332008549449961,031
Total liabilities1,4081,2121,0281,5471,5941,6511,691
Assets
Gross block6996555631,3331,3191,3161,356
Net block304273192587629752843
Capital work in progress12.410.0051.247.7110.3118.8411.45
Investments33026916785.1211155.3326.36
Inventories14310764.09428414354343
Sundry debtors189160259469428400385
Cash & bank balances4154104889.969.389.958.84
Loans & advances11676.8041.71167146101108
Total current assets8637548521,074998866845
Total current liabilities246210380241209166169
Net working capital617545472833789700675
Total assets1,4081,2121,0281,5471,5941,6511,691
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash41048823.289.389.958.8429.09
Net cash from operating activities(40.19)(45.30)(166)183136135123
Net cash from investing activities(100)(110)(27.71)(13.69)2.76(10.17)(10.15)
Net cash from financing activities14577.44658(168)(140)(124)(133)
Net change in cash4.90(77.53)4640.58(0.57)1.11(20.25)
Closing cash4154104889.969.389.958.84
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+15.7%-67.1%+45.2%+16.6%+15.4%+13.9%-
EBITDA growth+372.3%-104.3%+52.9%+1.8%+6.4%+27.2%-
PBT growth-81.0%-55.5%+650.0%+889.9%-50.4%+9998.0%-
Net income growth+529.8%-94.5%+161.7%+2273.5%+41.6%+78.9%-
Revenue CAGR (3Y)-18.0%-17.1%+25.0%+15.3%+10.9%+5.4%+2.7%
EBITDA CAGR (3Y)-43.5%-+18.3%+11.3%+15.3%+13.0%+12.7%
Profitability & leverage
Net income margin+6.7%+45.6%+32.1%+3.7%-0.6%-0.5%-2.8%
Return on capital employed+4.4%+1.1%+18.8%+14.2%0.0%0.0%0.0%
Return on net worth+3.7%-0.2%+16.9%+11.6%0.0%0.0%0.0%
Debt / equity0.010.110.811.942.252.392.83
Long-term debt / equity0.010.100.711.711.992.092.41
Interest cover30.04-11.7347.5166.75156.51107.52207.13
Efficiency & per share
Fixed asset turnover0.940.921.951.010.890.770.66
Inventory turnover5.086.566.802.742.572.462.28
Debtors turnover3.642.684.592.572.392.182.09
EPS (₹)4.9037.2579.777.10(0.95)(0.74)(3.48)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)157.74158.56118.7582.2672.9171.5570.15

Similar companies to Ind Swift

Ind Swift has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Laurus Labs
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
Symbiotec
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
SeQuent
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed similar companies of Ind Swift

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Ind Swift

The website of Ind Swift (indswiftlabs.com) receives about 4.2K visits a month and ranks #3,680,932 among all websites worldwide, #4,726 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    4.2K

    ▼ 15.4% vs previous month

  • Unique visitors
    2K

    per month

  • Global rank
    #3,680,932

    among all websites

  • Category rank
    #4,726

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Ind Swift. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Ind-Swift
indswiftltd.com
100%
1.5K#8,422,180View details
Index Pharmaceutical
indexpharmaceuticals.com
61%
1.4K#12,189,341View details
farmhispania.com
farmhispania.com
60%
–
Teva Active Pharmaceutical Ingredients
tapi.com
60%
10.5K#2,692,209View details
Ra Chem Pharma
rachempharma.com
60%
View details
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 6 similar websites and full traffic analytics for Ind Swift

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Ind Swift (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ind Swift

INDSWFTLAB: Q2 CONS NET PROFIT 342M RUPEES VS 80M (YOY)
Exchange Update • 8 days ago
INDSWFTLAB: Q2 EBITDA 455M RUPEES VS 75M (YOY); Q2 EBITDA MARGIN 18.9% VS 4.7% (YOY)
Exchange Update • 8 days ago
Ind Swift Laboratories Upgrading Manufacturing Facility Located At J&K To EU-GMP/Pics Standards
Reuters • 2 months ago
Ind Swift Laboratories June-Quarter Consol Net PAT 246.8 Million Rupees
Reuters • 2 months ago
Ind Swift Laboratories Enters MoU With Him Infratech For Warehouse Construction On July 28, 2026
Reuters • 3 months ago
Ind Swift Laboratories To Consider Raising Of Funds By Way Of Issuance Of One Or More Instruments
Reuters • 4 months ago
Rajesh Palviya of Axis Sec suggests JSW Infrastructure, Ind-Swift Laboratories, Welspun Living shares to buy next week | Stock Market News
mint • 4 months ago
HCP Investments sells 7.45% stake in Ind-Swift Laboratories in three days
Moneycontrol • 6 months ago
Ind Swift Laboratories Says Tribunal Rejected All Claims Of PI Industries, Counterclaims Of Co, Others
Reuters • 7 months ago
Ind Swift Laboratories Ltd To Invest 400 Million Rupees In Samba Facility Upgrade
Reuters • 8 months ago
Premium access

Complete news archive for Ind Swift

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ind Swift

Ind Swift was founded in 1995.

Ind Swift is headquartered in Chandigarh, India.

Gopal Munjal is the CEO of Ind Swift, as recorded in our data.

Ind Swift has 1,250 employees.

The primary company behind Ind Swift, Ind Swift Laboratories Limited, reported revenue of ₹688 Cr for FY 2026, up 13% year on year.

Ind-Swift Laboratories Ltd. was established in 1995 in Chandigarh, India, focusing on API manufacturing and CRAMS in the pharmaceutical sector. Operations span six manufacturing sites across India and an independent RD center, enabling API development, finished dosage forms, and non-infringing processes. Services include custom synthesis, preclinical supply, process RD, contract manufacturing of HPAPIs, and analytical plus regulatory support. Facilities are approved by FDA, EDQM, TGA, PMDA, KFDA, and other agencies.

Ind Swift's top competitors include Laurus Labs, Symbiotec and SeQuent.

Ind Swift offers APIs, Formulations, CRAMS, and Research Services.

Yes, Ind Swift is publicly traded on NSE under the ticker symbol INDSWFTLAB.

Ind Swift operates through Ind Swift Laboratories Limited.

The legal entities of Ind Swift currently have 10 directors, including Rishav Mehta, Himanshu Jain, Sahil Munjal and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available